```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                   170.97      571.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                     0.00       -7.02

FILE 'REGISTRY' ENTERED AT 20:08:01 ON 25 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 NOV 2007  HIGHEST RN 955880-04-3
DICTIONARY FILE UPDATES:  23 NOV 2007  HIGHEST RN 955880-04-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\EBernhardt\My
Documents\Stnexp\Queries\10571405.str
```



```
chain nodes :
17  18  19  20
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16
chain bonds :
17-18  17-19  17-20
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  10-13  11-12  11-16
13-14  14-15  15-16
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  5-6  17-18  17-19  17-20
normalized bonds :
7-8  7-12  8-9  9-10  10-11  10-13  11-12  11-16  13-14  14-15  15-16


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
20:Atom  21:Atom  22:Atom



L10     STRUCTURE UPLOADED

=> s l10
SAMPLE SEARCH INITIATED 20:08:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      552 TO ITERATE

100.0% PROCESSED      552 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:         9631 TO    12449
PROJECTED ANSWERS:               4 TO      200

L11           4 SEA SSS SAM L10

=> s l10 sss full
FULL SEARCH INITIATED 20:08:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    11320 TO ITERATE

100.0% PROCESSED    11320 ITERATIONS                            108 ANSWERS
SEARCH TIME: 00.00.01

L12         108 SEA SSS FUL L10

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                172.55     744.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                  0.00      -7.02
```

FILE 'CAPLUS' ENTERED AT 20:09:03 ON 25 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Nov 2007 VOL 147 ISS 23
FILE LAST UPDATED: 23 Nov 2007 (20071123/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l11
L13 3 L11

=> d l13 1-3 bib abs hitstr

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:493996 CAPLUS
DN 145:8187
TI Preparation of isotopomeric piperazine-containing ligands labeling and diagnostic imaging of 5-HT6 receptors
IN Gee, Antony David; Martarello, Laurent; Johnson, Christopher Norbert; Witty, David R.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006053785	A1	20060526	WO 2005-EP12463	20051117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM
CA 2588381 A1 20060526 CA 2005-2588381 20051117
EP 1824830 A1 20070829 EP 2005-807786 20051117
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
PRAI GB 2004-25548 A 20041119
WO 2005-EP12463 W 20051117
OS CASREACT 145:8187; MARPAT 145:8187
GI



I

AB Piperazine-containing ligands [I; R1 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; R2 = F; or R1 = C1-4 (fluoro)alkyl and R2 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; e.g., (11C-N-methyl)-3-[(3-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline; 5-HT6 receptor pKi 9.82], which are useful for the labeling and diagnostic imaging of 5-HT6 receptors functionality and the treatment of CNS related disorders, are prepared
IT 607743-50-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of isotopomeric piperazine-containing ligands labeling and
diagnostic imaging of 5-HT6 receptors)
RN 607743-50-0 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:260030 CAPLUS
DN 142:336394
TI Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders
IN Johnson, Christopher Norbert; Witty, David R.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026125	A1	20050324	WO 2004-EP10129	20040909
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663980	A1	20060607	EP 2004-765057	20040909
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007505075	T	20070308	JP 2006-525773	20040909
	US 2006287334	A1	20061221	US 2006-571405	20060310
PRAI	GB 2003-21473	A	20030912		
	WO 2004-EP10129	W	20040909		

OS CASREACT 142:336394; MARPAT 142:336394
GI



AB Title compds. I [R1 = (un)substituted alkyl, alkylcycloalkyl, alkoxyalkyl, alkyl(hetero)aryl, alkylheterocyclyl; R2 = H or alkyl; m = 1-4; when m > 1, two R2 groups may be linked to form a CH2, (CH2)2 or (CH2)3 group; R3-R5 = independently H, halo, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, CONH2 and derivs.; n = 1 - 3; p = 1-2; and their pharmaceutically acceptable salts] were prepared as 5HT6 receptor antagonists in treatment of CNS disorders. Thus, condensation of 3-phenylsulfonyl-8-(piperazin-1-yl)quinoline (preparation given) with 4-fluorobenzaldehyde gave II. I were tested and showed good affinity for the 5-HT6 receptor, having pKi values ≥ 7.0 at human cloned 5-HT6 receptors.

IT 848396-04-3P, 8-(4-Cyclopropylmethylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)

RN 848396-04-3 CAPLUS

CN Quinoline, 8-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:777764 CAPLUS

DN 139:292163

TI Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders

IN Ahmed, Mahmood; Johnson, Christopher Norbert; Jones, Martin C.; MacDonald, Gregor James; Moss, Stephen Frederick; Thompson, Mervyn; Wade, Charles Edward; Witty, David

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080580	A2	20031002	WO 2003-EP3197	20030325
	WO 2003080580	A3	20040205		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2479786	A1	20031002	CA 2003-2479786	20030325
	AU 2003219103	A1	20031008	AU 2003-219103	20030325
	EP 1497266	A2	20050119	EP 2003-714889	20030325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008696	A	20050125	BR 2003-8696	20030325
	CN 1656075	A	20050817	CN 2003-811644	20030325
	JP 2005531518	T	20051020	JP 2003-578335	20030325
	TW 268928	B	20061221	TW 2003-92106558	20030325
	RU 2309154	C2	20071027	RU 2004-131641	20030325
	ZA 2004007320	A	20051004	ZA 2004-7320	20040912
	IN 2004DN02703	A	20070302	IN 2004-DN2703	20040914
	MX 2004PA09318	A	20050125	MX 2004-PA9318	20040924
	US 2005124628	A1	20050609	US 2004-509078	20040927
	NO 2004004588	A	20041025	NO 2004-4588	20041025
PRAI	GB 2002-7289	A	20020327		
	GB 2002-25678	A	20021104		
	WO 2003-EP3197	W	20030325		

OS MARPAT 139:292163

GI



I

AB Title compds. I [R1, R2 = H, alkyl; R1R2, R22 = (CH2)2-4; R3-R5 = H, halogen, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, (un)substituted CONH2; A = (un)substituted aryl; m = 1-4; n = 1-3, p = 1, 2] were prepared for use as HT6 receptor antagonists in treatment of CNS disorders. Thus, 8-iodo-3-phenylsulfonylquinoline was prepared from 8-nitroquinoline and was treated with 1-tert.-butoxycarbonylpiperazine, followed by deblocking, to give 3-phenylsulfonyl-8-piperazinoquinoline.

IT 607742-63-2P 607742-78-9P 607743-50-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)

RN 607742-63-2 CAPLUS

CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-78-9 CAPLUS

CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607743-50-0 CAPLUS

CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX

NAME)



```
=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    19.57     763.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -2.34      -9.36

FILE 'CAOLD' ENTERED AT 20:13:38 ON 25 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REGlstRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> d his

     (FILE 'HOME' ENTERED AT 18:18:31 ON 25 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 18:19:07 ON 25 NOV 2007
L1             STRUCTURE UPLOADED
L2               1 S L1
L3             416 S L1 SSS FULL
```

```
     FILE 'CAPLUS' ENTERED AT 18:20:37 ON 25 NOV 2007
L4           369 S L3

     FILE 'REGISTRY' ENTERED AT 18:20:54 ON 25 NOV 2007

     FILE 'REGISTRY' ENTERED AT 18:25:33 ON 25 NOV 2007
L5               STRUCTURE UPLOADED
L6            67 S L5 SSS FULL

     FILE 'CAPLUS' ENTERED AT 18:26:54 ON 25 NOV 2007
L7             9 S L6

     FILE 'CAOLD' ENTERED AT 18:27:33 ON 25 NOV 2007
L8             0 S L6

     FILE 'CHEMCATS' ENTERED AT 18:27:43 ON 25 NOV 2007
L9            84 S L6

     FILE 'REGISTRY' ENTERED AT 20:08:01 ON 25 NOV 2007
L10              STRUCTURE UPLOADED
L11            4 S L10
L12          108 S L10 SSS FULL

     FILE 'CAPLUS' ENTERED AT 20:09:03 ON 25 NOV 2007
L13            3 S L11

     FILE 'CAOLD' ENTERED AT 20:13:38 ON 25 NOV 2007

=> s l12
L14            0 L12

=> file chemcats
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.45     764.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -9.36

FILE 'CHEMCATS' ENTERED AT 20:13:52 ON 25 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)


FILE LAST UPDATED 17 NOVEMBER 2007 (20071117/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow
prompt.  For the list of suppliers currently in the file, enter
HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ.
For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP
CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis.  Please consult the
suppliers for current information regarding pricing, regional
availability, available quantities, purities, etc.  THERE ARE NO
```

WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 17 million records. See HELP CONTENT and NEWS FILE for details.

=> s l12
L15 0 L12

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.93	765.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-9.36

FILE 'REGISTRY' ENTERED AT 20:14:00 ON 25 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 NOV 2007 HIGHEST RN 955880-04-3
DICTIONARY FILE UPDATES: 23 NOV 2007 HIGHEST RN 955880-04-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d his

(FILE 'HOME' ENTERED AT 18:18:31 ON 25 NOV 2007)

FILE 'REGISTRY' ENTERED AT 18:19:07 ON 25 NOV 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 416 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:20:37 ON 25 NOV 2007
L4 369 S L3

FILE 'REGISTRY' ENTERED AT 18:20:54 ON 25 NOV 2007

```
     FILE 'REGISTRY' ENTERED AT 18:25:33 ON 25 NOV 2007
L5                STRUCTURE UPLOADED
L6             67 S L5 SSS FULL

     FILE 'CAPLUS' ENTERED AT 18:26:54 ON 25 NOV 2007
L7              9 S L6

     FILE 'CAOLD' ENTERED AT 18:27:33 ON 25 NOV 2007
L8              0 S L6

     FILE 'CHEMCATS' ENTERED AT 18:27:43 ON 25 NOV 2007
L9             84 S L6

     FILE 'REGISTRY' ENTERED AT 20:08:01 ON 25 NOV 2007
L10               STRUCTURE UPLOADED
L11             4 S L10
L12           108 S L10 SSS FULL

     FILE 'CAPLUS' ENTERED AT 20:09:03 ON 25 NOV 2007
L13             3 S L11

     FILE 'CAOLD' ENTERED AT 20:13:38 ON 25 NOV 2007
L14             0 S L12

     FILE 'CHEMCATS' ENTERED AT 20:13:52 ON 25 NOV 2007
L15             0 S L12

     FILE 'REGISTRY' ENTERED AT 20:14:00 ON 25 NOV 2007

=> s l12 and caplus/lc
      55615820 CAPLUS/LC
L16         108 L12 AND CAPLUS/LC

=> s l12 not l16
L17             0 L12 NOT L16

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     7.20     772.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -9.36

FILE 'CAPLUS' ENTERED AT 20:17:16 ON 25 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 25 Nov 2007 VOL 147 ISS 23
FILE LAST UPDATED: 23 Nov 2007 (20071123/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 18:18:31 ON 25 NOV 2007)

FILE 'REGISTRY' ENTERED AT 18:19:07 ON 25 NOV 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 416 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:20:37 ON 25 NOV 2007
L4 369 S L3

FILE 'REGISTRY' ENTERED AT 18:20:54 ON 25 NOV 2007

FILE 'REGISTRY' ENTERED AT 18:25:33 ON 25 NOV 2007
L5 STRUCTURE UPLOADED
L6 67 S L5 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:26:54 ON 25 NOV 2007
L7 9 S L6

FILE 'CAOLD' ENTERED AT 18:27:33 ON 25 NOV 2007
L8 0 S L6

FILE 'CHEMCATS' ENTERED AT 18:27:43 ON 25 NOV 2007
L9 84 S L6

FILE 'REGISTRY' ENTERED AT 20:08:01 ON 25 NOV 2007
L10 STRUCTURE UPLOADED
L11 4 S L10
L12 108 S L10 SSS FULL

FILE 'CAPLUS' ENTERED AT 20:09:03 ON 25 NOV 2007
L13 3 S L11

FILE 'CAOLD' ENTERED AT 20:13:38 ON 25 NOV 2007
L14 0 S L12

FILE 'CHEMCATS' ENTERED AT 20:13:52 ON 25 NOV 2007
L15 0 S L12

FILE 'REGISTRY' ENTERED AT 20:14:00 ON 25 NOV 2007
L16 108 S L12 AND CAPLUS/LC
L17 0 S L12 NOT L16

FILE 'CAPLUS' ENTERED AT 20:17:16 ON 25 NOV 2007

=> s l12
L18 7 L12

=> d l18 1-7 bib abs hitstr

L18 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:410374 CAPLUS
DN 146:402011
TI Process for preparation of 8-amino-3-phenylsulfonylquinolines from 8-fluoro-3-phenylsulfonylquinoline and amines in the presence of base and solvent.
IN Wade, Charles Edward
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 26pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007039238	A1	20070412	WO 2006-EP9460	20060926
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	GB 2005-19758	A	20050928		

OS CASREACT 146:402011; MARPAT 146:402011
GI



I

AB Title compds. [I; R1, R2 = H, alkyl; NR1R2 = (substituted) 4-7 membered heterocyclyl], were prepared by reaction of 8-fluoro-3-phenylsulfonylquinoline with R1R2NH (variables as above) in the presence of base and solvent. Thus, 8-fluoro-3-phenylsulfonylquinoline (preparation given), piperazine, and K2CO3 were heated together in n-propanol at 100° for 23 h to give 86% 3-phenylsulfonyl-8-piperazin-1-ylquinoline. Polymorphic forms II and III of the latter were prepared via

recrystn.

IT 607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of aminophenylsulfonylquinolines from fluorophenylsulfonylquinolines and amines in the presence of base and solvent)

RN 607742-69-8 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:493996 CAPLUS

DN 145:8187

TI Preparation of isotopomeric piperazine-containing ligands labeling and diagnostic imaging of 5-HT6 receptors

IN Gee, Antony David; Martarello, Laurent; Johnson, Christopher Norbert; Witty, David R.

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006053785	A1	20060526	WO 2005-EP12463	20051117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2588381	A1	20060526	CA 2005-2588381	20051117

EP 1824830 A1 20070829 EP 2005-807786 20051117
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
PRAI GB 2004-25548 A 20041119
WO 2005-EP12463 W 20051117
OS CASREACT 145:8187; MARPAT 145:8187
GI



I

AB Piperazine-containing ligands [I; R1 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; R2 = F; or R1 = C1-4 (fluoro)alkyl and R2 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; e.g., (11C-N-methyl)-3-[(3-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline; 5-HT6 receptor pKi 9.82], which are useful for the labeling and diagnostic imaging of 5-HT6 receptors functionality and the treatment of CNS related disorders, are prepared
IT 607743-50-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of isotopomeric piperazine-containing ligands labeling and
diagnostic imaging of 5-HT6 receptors)
RN 607743-50-0 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



IT 887923-36-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isotopomeric piperazine-containing ligands labeling and diagnostic imaging of 5-HT6 receptors)
RN 887923-36-6 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-[4-(methyl-11C)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:395276 CAPLUS
DN 142:430310
TI Process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline
IN Gladwin, Asa Elisabeth
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005040124	A1	20050506	WO 2004-EP10843	20040923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283805	A1	20050506	AU 2004-283805	20040923
CA 2540022	A1	20050506	CA 2004-2540022	20040923

	EP 1667975	A1	20060614	EP 2004-765655	20040923
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1856471	A	20061101	CN 2004-80027527	20040923
	BR 2004014678	A	20061128	BR 2004-14678	20040923
	JP 2007506702	T	20070322	JP 2006-527373	20040923
	IN 2006DN00970	A	20070817	IN 2006-DN970	20060224
	US 2007032504	A1	20070208	US 2006-572670	20060320
	MX 2006PA03375	A	20060608	MX 2006-PA3375	20060324
	KR 2007020372	A	20070221	KR 2006-705895	20060324
	NO 2006001791	A	20060424	NO 2006-1791	20060424
PRAI	GB 2003-22629	A	20030926		
	WO 2004-EP10843	W	20040923		

OS CASREACT 142:430310

AB Polymorphic crystalline forms of 3-phenylsulfonyl-8-piperazin-1-ylquinoline are synthesized, characetrized, and claimed in the treatment of CNS (e.g., schizophrenia) and other disorders.

IT 607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline)

RN 607742-69-8 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:260030 CAPLUS

DN 142:336394

TI Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders

IN Johnson, Christopher Norbert; Witty, David R.

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026125	A1	20050324	WO 2004-EP10129	20040909

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1663980 A1 20060607 EP 2004-765057 20040909
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007505075 T 20070308 JP 2006-525773 20040909

US 2006287334 A1 20061221 US 2006-571405 20060310

PRAI GB 2003-21473 A 20030912

WO 2004-EP10129 W 20040909

OS CASREACT 142:336394; MARPAT 142:336394

GI



AB Title compds. I [R1 = (un)substituted alkyl, alkylcycloalkyl, alkoxyalkyl, alkyl(hetero)aryl, alkylheterocyclyl; R2 = H or alkyl; m = 1-4; when m > 1, two R2 groups may be linked to form a CH2, (CH2)2 or (CH2)3 group; R3-R5 = independently H, halo, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, CONH2 and derivs.; n = 1 - 3; p = 1-2; and their pharmaceutically acceptable salts] were prepared as 5HT6 receptor antagonists in treatment of CNS disorders. Thus, condensation of 3-phenylsulfonyl-8-(piperazin-1-yl)quinoline (preparation given) with 4-fluorobenzaldehyde gave II. I were tested and showed good affinity for the 5-HT6 receptor, having pKi values ≥ 7.0 at human cloned 5-HT6 receptors.

IT 848396-13-4P, 8-[4-(4-Fluorobenzyl)piperazin-1-yl]-3-phenylsulfonylquinoline
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)
RN 848396-13-4 CAPLUS
CN Quinoline, 8-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-3-(phenylsulfonyl)-
(CA INDEX NAME)



IT 848396-03-2P, 8-[4-(4-Fluorobenzyl)piperazin-1-yl]-3-phenylsulfonylquinoline hydrochloride 848396-04-3P, 8-(4-Cyclopropylmethylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride 848396-05-4P, 8-[4-(Cyclohexyl)piperazin-1-yl]-3-phenylsulfonylquinoline hydrochloride 848396-07-6P, 8-(4-Cyclopentylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride 848396-08-7P, 8-(4-Cyclobutylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride 848396-09-8P, 8-(4-Cyclopropylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride 848396-11-2P, 8-[4-(2-Methoxyethyl)piperazin-1-yl]-3-phenylsulfonylquinoline hydrochloride 848396-12-3P, 8-[4-(2,2,2-Trifluoroethyl)piperazin-1-yl]-3-(4-fluorophenylsulfonyl)quinoline 848396-14-5P, 8-(4-Cyclopropylmethylpiperazin-1-yl)-3-phenylsulfonylquinoline 848396-15-6P, 8-[4-(Cyclohexyl)piperazin-1-yl]-3-phenylsulfonylquinoline 848396-16-7P, 8-(4-Cyclopentylpiperazin-1-yl)-3-phenylsulfonylquinoline 848396-17-8P, 8-(4-Cyclobutylpiperazin-1-yl)-3-phenylsulfonylquinoline 848396-18-9P, 8-(4-Cyclopropylpiperazin-1-yl)-3-phenylsulfonylquinoline 848396-19-0P, 8-[4-(2-Methoxyethyl)piperazin-1-yl]-3-phenylsulfonylquinoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)
RN 848396-03-2 CAPLUS
CN Quinoline, 8-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-04-3 CAPLUS
CN Quinoline, 8-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-05-4 CAPLUS
CN Quinoline, 8-(4-cyclohexyl-1-piperazinyl)-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-07-6 CAPLUS
CN Quinoline, 8-(4-cyclopentyl-1-piperazinyl)-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-08-7 CAPLUS
CN Quinoline, 8-(4-cyclobutyl-1-piperazinyl)-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-09-8 CAPLUS
CN Quinoline, 8-(4-cyclopropyl-1-piperazinyl)-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-11-2 CAPLUS
CN Quinoline, 8-[4-(2-methoxyethyl)-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-12-3 CAPLUS
CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 848396-14-5 CAPLUS
CN Quinoline, 8-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 848396-15-6 CAPLUS
CN Quinoline, 8-(4-cyclohexyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 848396-16-7 CAPLUS
CN Quinoline, 8-(4-cyclopentyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 848396-17-8 CAPLUS
CN Quinoline, 8-(4-cyclobutyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 848396-18-9 CAPLUS
CN Quinoline, 8-(4-cyclopropyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 848396-19-0 CAPLUS
CN Quinoline, 8-[4-(2-methoxyethyl)-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



IT 607742-54-1P, 8-(4-Methylpiperazin-1-yl)-3-phenylsulfonylquinoline
607742-55-2P, 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline hydrochloride 607742-69-8P, 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline 607743-10-2P, 8-(4-tert-Butoxycarbonylpiperazin-1-yl)-3-phenylsulfonylquinoline 607743-42-0P, 8-(4-Methylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)
RN 607742-54-1 CAPLUS
CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 607742-55-2 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-10-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-(phenylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 607743-42-0 CAPLUS
CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:216810 CAPLUS
DN 142:298134
TI Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders
IN Johnson, Christopher Norbert; Moss, Stephen Frederick; Tait, Malcolm M.; Witty, David R.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005021530	A1	20050310	WO 2004-EP9724	20040826
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1660483	A1	20060531	EP 2004-764687	20040826
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007504114	T	20070301	JP 2006-524347	20040826
PRAI	GB 2003-20320	A	20030829		
	WO 2004-EP9724	W	20040826		

OS MARPAT 142:298134
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, (un)substituted cyclo/alkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl; R2 = H, alkyl; m = 1-4; when m > 1, two R2 groups may be linked to form a CH2, (CH2)2 or (CH2)3 group; when R1 = alkyl, R1 may optionally be linked to R2 to form a (CH2)2, (CH2)3 or (CH2)4 group; R3, R4, R5 = independently H, halo, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, CONH2 and derivs.; n = 1 - 3; X = (CH2)p; p = 1-2; Ra = H, alk(en)yl, alkyl/cycloalkyl; Rb = H, alkyl, (un)substituted alkylaryl, alkylheteroaryl; or RaNRb = (un)substituted heterocyclyl; and their pharmaceutically acceptable salts] were prepared for use as 5HT6 receptor antagonists in treatment of CNS disorders. Thus, II•HCl was prepared by oxidation of 8-chloro-3-quinolinethiol (preparation given), oxidative cleavage of disulfide, amination of the chloride with 1,1-dimethylethyl 1-piperazinecarboxylate and Boc-deprotection. I were tested and showed good affinity for the 5-HT6 receptor, having pKi values ≥ 7.5 at human cloned 5-HT6 receptors.

IT 847727-11-1P, 3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(1-piperazinyl)quinoline monohydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of piperazinylquinolines for treatment of CNS disorders)

RN 847727-11-1 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]-,

monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 847727-12-2P, 3-[(5-Fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-8-(1-piperazinyl)quinoline monohydrochloride 847727-13-3P, 8-(1-Piperazinyl)-3-[(1-piperidinyl)sulfonyl]quinoline monohydrochloride 847727-14-4P, 3-(Morpholin-4-ylsulfonyl)-8-(1-piperazinyl)quinoline monohydrochloride 847727-15-5P, 3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline monohydrochloride 847727-16-6P, 3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(1-piperazinyl)quinoline 847727-17-7P, 3-[(5-Fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-8-(1-piperazinyl)quinoline 847727-18-8P, 8-(1-Piperazinyl)-3-[(1-piperidinyl)sulfonyl]quinoline 847727-19-9P, 3-(Morpholin-4-ylsulfonyl)-8-(1-piperazinyl)quinoline 847727-20-2P, 3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperazinylquinolines for treatment of CNS disorders)

RN 847727-12-2 CAPLUS

CN 1H-Isoindole, 5-fluoro-2,3-dihydro-2-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847727-13-3 CAPLUS
CN Piperidine, 1-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847727-14-4 CAPLUS
CN Morpholine, 4-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847727-15-5 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(4-methyl-1-piperazinyl)-3-quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847727-16-6 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 847727-17-7 CAPLUS
CN 1H-Isoindole, 5-fluoro-2,3-dihydro-2-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 847727-18-8 CAPLUS
CN Piperidine, 1-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 847727-19-9 CAPLUS
CN Morpholine, 4-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 847727-20-2 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(4-methyl-1-piperazinyl)-3-quinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 847727-30-4P, 1,1-Dimethylethyl 4-[3-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-8-quinolinyl]-1-piperazinecarboxylate 847727-31-5P, 1,1-Dimethylethyl 4-[3-[(5-fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-8-quinolinyl]-1-piperazinecarboxylate 847727-32-6P, 1,1-Dimethylethyl 4-[3-(1-piperidinylsulfonyl)-8-quinolinyl]-1-piperazinecarboxylate 847727-33-7P, 1,1-Dimethylethyl 4-[3-(4-morpholinylsulfonyl)-8-quinolinyl]-1-piperazinecarboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperazinylquinolines for treatment of CNS disorders)
RN 847727-30-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847727-31-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)sulfonyl]-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847727-32-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-(1-piperidinylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847727-33-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-(4-morpholinylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:777791 CAPLUS
DN 139:292272
TI Preparation of arylsulfonylquinolinyl- of azaindolylpiperazines as 5-HT6 antagonists
IN Johnson, Christopher Norbert; MacDonald, Gregor James; Mitchell, Darren Jason; Moss, Stephen Frederick; Thompson, Mervyn; Witty, David
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080608	A2	20031002	WO 2003-EP3195	20030325

```
     WO 2003080608        A3    20040205
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003226724        A1    20031008    AU 2003-226724         20030325
     EP 1497291           A2    20050119    EP 2003-744860         20030325
     EP 1497291           B1    20061122
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005527542        T     20050915    JP 2003-578362         20030325
     AT 346068            T     20061215    AT 2003-744860         20030325
     ES 2277098           T3    20070701    ES 2003-3744860        20030325
     US 2005124626        A1    20050609    US 2004-509077         20040927
PRAI GB 2002-7275         A     20020327
     GB 2002-7278         A     20020327
     GB 2002-7281         A     20020327
     GB 2002-7282         A     20020327
     WO 2003-EP3195       W     20030325
OS   MARPAT 139:292272
GI
```




```
AB   Title compds. I [R1, R2 = H, alkyl; R1R2, R22 = (CH2)1-4; Q =
     (un)substituted quinolinyl, pyrrolopyridinyl; A = (un)substituted aryl; m
     = 1-4; p = 1, 2] were prepared for use as 5-HT6 antagonists in the treatment
     of CNS and other disorders.  Thus, 3-chloro-4-nitropyridine was treated
     with 1-tert.-butoxycarbonylpiperazine, cyclized with CH2:CHMgBr to
     7-tert.-butoxycarbonylpiperazin-1-yl-1H-pyrrolo[3,2-b]pyridine, which was
     treated with Ph2S2, oxidized to the sulfone. and deblocked to give the
     title compound II.
IT   608142-86-5P 608142-88-7P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (preparation of arylsulfonylquinolinyl- of azaindolylpiperazines as 5-HT6
```

antagonists)
RN 608142-86-5 CAPLUS
CN Quinoline, 4-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RN 608142-88-7 CAPLUS
CN Quinoline, 2-methyl-4-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



IT 608142-87-6P 608142-89-8P 608142-90-1P
608142-91-2P 608142-92-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylquinolinyl- of azaindolylpiperazines as 5-HT6 antagonists)
RN 608142-87-6 CAPLUS
CN Quinoline, 4-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 608142-89-8 CAPLUS
CN Quinoline, 2-methyl-4-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 608142-90-1 CAPLUS
CN Quinoline, 4-[(2-fluorophenyl)sulfonyl]-2-methyl-8-(1-piperazinyl)- (CA INDEX NAME)



RN 608142-91-2 CAPLUS
CN Quinoline, 4-[(3-fluorophenyl)sulfonyl]-2-methyl-8-(1-piperazinyl)- (CA INDEX NAME)



RN 608142-92-3 CAPLUS
CN Quinoline, 4-[(3-chlorophenyl)sulfonyl]-2-methyl-8-(1-piperazinyl)- (CA INDEX NAME)



IT 608143-05-1P 608143-10-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonylquinolinyl- of azaindolylpiperazines as 5-HT6 antagonists)
RN 608143-05-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-(phenylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 608143-10-8 CAPLUS
CN Piperazine, 1-[2-methyl-4-(phenylsulfonyl)-8-quinolinyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:777764 CAPLUS
DN 139:292163
TI Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders
IN Ahmed, Mahmood; Johnson, Christopher Norbert; Jones, Martin C.; MacDonald, Gregor James; Moss, Stephen Frederick; Thompson, Mervyn; Wade, Charles Edward; Witty, David
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080580	A2	20031002	WO 2003-EP3197	20030325
	WO 2003080580	A3	20040205		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2479786	A1	20031002	CA 2003-2479786	20030325
	AU 2003219103	A1	20031008	AU 2003-219103	20030325
	EP 1497266	A2	20050119	EP 2003-714889	20030325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008696	A	20050125	BR 2003-8696	20030325
	CN 1656075	A	20050817	CN 2003-811644	20030325
	JP 2005531518	T	20051020	JP 2003-578335	20030325

	TW 268928	B	20061221	TW 2003-92106558	20030325
	RU 2309154	C2	20071027	RU 2004-131641	20030325
	ZA 2004007320	A	20051004	ZA 2004-7320	20040912
	IN 2004DN02703	A	20070302	IN 2004-DN2703	20040914
	MX 2004PA09318	A	20050125	MX 2004-PA9318	20040924
	US 2005124628	A1	20050609	US 2004-509078	20040927
	NO 2004004588	A	20041025	NO 2004-4588	20041025
PRAI	GB 2002-7289	A	20020327		
	GB 2002-25678	A	20021104		
	WO 2003-EP3197	W	20030325		
OS	MARPAT 139:292163				
GI					



I

AB Title compds. I [R1, R2 = H, alkyl; R1R2, R22 = (CH2)2-4; R3-R5 = H, halogen, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, (un)substituted CONH2; A = (un)substituted aryl; m = 1-4; n = 1-3, p = 1, 2] were prepared for use as HT6 receptor antagonists in treatment of CNS disorders. Thus, 8-iodo-3-phenylsulfonylquinoline was prepared from 8-nitroquinoline and was treated with 1-tert.-butoxycarbonylpiperazine, followed by deblocking, to give 3-phenylsulfonyl-8-piperazinoquinoline.

IT 607743-10-2P 607743-11-3P 607743-43-1P
607743-44-2P 607743-45-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)

RN 607743-10-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-(phenylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 607743-11-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[[3-(trifluoromethyl)phenyl]sulfonyl]-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 607743-43-1 CAPLUS
CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607743-44-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 3-methyl-4-[3-(phenylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-45-3 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[3-(phenylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester, (1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 607742-55-2P 607742-69-8P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)
RN 607742-55-2 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



IT 607742-54-1P 607742-56-3P 607742-57-4P
607742-58-5P 607742-59-6P 607742-60-9P
607742-61-0P 607742-62-1P 607742-63-2P
607742-64-3P 607742-65-4P 607742-66-5P
607742-68-7P 607742-70-1P 607742-71-2P
607742-72-3P 607742-73-4P 607742-74-5P
607742-75-6P 607742-76-7P 607742-77-8P
607742-78-9P 607742-79-0P 607742-80-3P
607742-81-4P 607742-82-5P 607742-83-6P
607742-84-7P 607742-85-8P 607742-86-9P
607742-87-0P 607742-88-1P 607742-89-2P
607742-90-5P 607742-92-7P 607742-93-8P
607742-94-9P 607742-95-0P 607742-96-1P
607742-97-2P 607742-98-3P 607742-99-4P
607743-00-0P 607743-01-1P 607743-02-2P
607743-03-3P 607743-04-4P 607743-42-0P
607743-46-4P 607743-47-5P 607743-48-6P
607743-49-7P 607743-50-0P 607743-51-1P
607743-52-2P 607743-53-3P 607743-54-4P
607743-55-5P 607743-56-6P 607743-58-8P

607743-59-9P 607743-60-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)

RN 607742-54-1 CAPLUS
CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 607742-56-3 CAPLUS
CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-57-4 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-58-5 CAPLUS
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-59-6 CAPLUS
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-60-9 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-61-0 CAPLUS
CN Quinoline, 3-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-62-1 CAPLUS
CN Quinoline, 8-(1-piperazinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-63-2 CAPLUS
CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-64-3 CAPLUS
CN Quinoline, 6-methyl-3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-65-4 CAPLUS
CN Quinoline, 8-[(3R)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607742-66-5 CAPLUS
CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607742-68-7 CAPLUS
CN Quinoline, 8-[(2S)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607742-70-1 CAPLUS
CN Quinoline, 8-(4-ethyl-1-piperazinyl)-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-71-2 CAPLUS
CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-72-3 CAPLUS
CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-73-4 CAPLUS
CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-74-5 CAPLUS
CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-75-6 CAPLUS
CN Quinoline, 8-(1-piperazinyl)-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 607742-76-7 CAPLUS
CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607742-77-8 CAPLUS
CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607742-78-9 CAPLUS
CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607742-79-0 CAPLUS
CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607742-80-3 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607742-81-4 CAPLUS
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607742-82-5 CAPLUS
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607742-83-6 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 607742-84-7 CAPLUS
CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 607742-85-8 CAPLUS
CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607742-86-9 CAPLUS

CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-87-0 CAPLUS
CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-88-1 CAPLUS
CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-89-2 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-90-5 CAPLUS
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-92-7 CAPLUS
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-93-8 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-94-9 CAPLUS
CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607742-95-0 CAPLUS
CN Quinoline, 8-[(2R)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607742-96-1 CAPLUS
CN Quinoline, 8-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-3-(phenylsulfonyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 607742-97-2 CAPLUS
CN Quinoline, 8-(3,3-dimethyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 607742-98-3 CAPLUS

CN Quinoline, 8-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-3-(phenylsulfonyl)-
(CA INDEX NAME)



RN 607742-99-4 CAPLUS
CN Quinoline, 8-[4-(1-methylethyl)-1-piperazinyl]-3-(phenylsulfonyl)- (CA
INDEX NAME)



RN 607743-00-0 CAPLUS
CN Quinoline, 8-[4-(2-methylpropyl)-1-piperazinyl]-3-(phenylsulfonyl)- (CA
INDEX NAME)



RN 607743-01-1 CAPLUS

CN Quinoline, 8-[4-(2,2-dimethylpropyl)-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 607743-02-2 CAPLUS
CN Quinoline, 8-[(3R)-3,4-dimethyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-03-3 CAPLUS
CN Quinoline, 8-[(3S)-3,4-dimethyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-04-4 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[3-(phenylsulfonyl)-8-quinolinyl]-, monohydrochloride, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607743-42-0 CAPLUS
CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607743-46-4 CAPLUS
CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-47-5 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-48-6 CAPLUS

CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-49-7 CAPLUS
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-50-0 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-51-1 CAPLUS
CN Quinoline, 3-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-52-2 CAPLUS
CN Quinoline, 8-(1-piperazinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 607743-53-3 CAPLUS
CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-54-4 CAPLUS
CN Quinoline, 6-methyl-3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-55-5 CAPLUS
CN Quinoline, 8-[(3R)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-56-6 CAPLUS
CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-58-8 CAPLUS
CN Quinoline, 8-[(2S)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-59-9 CAPLUS
CN Quinoline, 8-(4-ethyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 607743-60-2 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[3-(phenylsulfonyl)-8-quinolinyl]-, (1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.




```
=> log h
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                39.24     811.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -5.46     -14.82

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 20:20:06 ON 25 NOV 2007
```